NCT06194448: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 1 year, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06194448 |
|---|---|
| Title | A Phase II, Open-label, Single-arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 21, 2024 |
| Completion date | July 7, 2026 |
| Required reporting date | July 7, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |